Literature DB >> 34983911

Adrenal G Protein-Coupled Receptors and the Failing Heart: A Long-distance, Yet Intimate Affair.

Jordana I Borges1, Krysten E Ferraino, Natalie Cora, Deepika Nagliya, Malka S Suster, Alexandra M Carbone, Anastasios Lymperopoulos.   

Abstract

ABSTRACT: Systolic heart failure (HF) is a chronic clinical syndrome characterized by the reduction in cardiac function and still remains the disease with the highest mortality worldwide. Despite considerable advances in pharmacological treatment, HF represents a severe clinical and social burden. Chronic human HF is characterized by several important neurohormonal perturbations, emanating from both the autonomic nervous system and the adrenal glands. Circulating catecholamines (norepinephrine and epinephrine) and aldosterone elevations are among the salient alterations that confer significant hormonal burden on the already compromised function of the failing heart. This is why sympatholytic treatments (such as β-blockers) and renin-angiotensin system inhibitors or mineralocorticoid receptor antagonists, which block the effects of angiotensin II (AngII) and aldosterone on the failing heart, are part of the mainstay HF pharmacotherapy presently. The adrenal gland plays an important role in the modulation of cardiac neurohormonal stress because it is the source of almost all aldosterone, of all epinephrine, and of a significant amount of norepinephrine reaching the failing myocardium from the blood circulation. Synthesis and release of these hormones in the adrenals is tightly regulated by adrenal G protein-coupled receptors (GPCRs), such as adrenergic receptors and AngII receptors. In this review, we discuss important aspects of adrenal GPCR signaling and regulation, as they pertain to modulation of cardiac function in the context of chronic HF, by focusing on the 2 best studied adrenal GPCR types in that context, adrenergic receptors and AngII receptors (AT 1 Rs). Particular emphasis is given to findings from the past decade and a half that highlight the emerging roles of the GPCR-kinases and the β-arrestins in the adrenals, 2 protein families that regulate the signaling and functioning of GPCRs in all tissues, including the myocardium and the adrenal gland.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34983911      PMCID: PMC9294064          DOI: 10.1097/FJC.0000000000001213

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.271


  107 in total

1.  Opposing effects of beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis : role of a pertussis toxin-sensitive G protein.

Authors:  C Communal; K Singh; D B Sawyer; W S Colucci
Journal:  Circulation       Date:  1999-11-30       Impact factor: 29.690

2.  Different potencies of angiotensin receptor blockers at suppressing adrenal β-Arrestin1-dependent post-myocardial infarction hyperaldosteronism.

Authors:  Anastasios Lymperopoulos; Emmanuel Sturchler; Ashley Bathgate-Siryk; Samalia Dabul; Dilayda Garcia; Karlee Walklett; Giuseppe Rengo; Patricia McDonald; Walter J Koch
Journal:  J Am Coll Cardiol       Date:  2014-12-30       Impact factor: 24.094

Review 3.  Class- and molecule-specific differential effects of angiotensin II type 1 receptor blockers.

Authors:  Satoshi Imaizumi; Shin-ichiro Miura; Eiji Yahiro; Yoshinari Uehara; Issei Komuro; Keijiro Saku
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

Review 4.  Cardiovascular manifestations of phaeochromocytoma.

Authors:  Aleksander Prejbisz; Jacques W M Lenders; Graeme Eisenhofer; Andrzej Januszewicz
Journal:  J Hypertens       Date:  2011-11       Impact factor: 4.844

5.  Structure-Function Basis of Attenuated Inverse Agonism of Angiotensin II Type 1 Receptor Blockers for Active-State Angiotensin II Type 1 Receptor.

Authors:  Takanobu Takezako; Hamiyet Unal; Sadashiva S Karnik; Koichi Node
Journal:  Mol Pharmacol       Date:  2015-06-29       Impact factor: 4.436

Review 6.  Mechanism of action of beta-blocking agents in heart failure.

Authors:  M R Bristow
Journal:  Am J Cardiol       Date:  1997-12-04       Impact factor: 2.778

7.  Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure.

Authors:  Kersten M Small; Lynne E Wagoner; Albert M Levin; Sharon L R Kardia; Stephen B Liggett
Journal:  N Engl J Med       Date:  2002-10-10       Impact factor: 91.245

8.  Expression of mRNAs for PACAP and its receptor in human neuroblastomas and their relationship to catecholamine synthesis.

Authors:  Kazumasa Isobe; Michio Kaneko; Setsuko Kaneko; Sumiko Nissato; Toru Nanmoku; Kazuhiro Takekoshi; Yukichi Okuda; Yasushi Kawakami
Journal:  Regul Pept       Date:  2004-12-15

Review 9.  Sartan-AT1 receptor interactions: in vitro evidence for insurmountable antagonism and inverse agonism.

Authors:  I Van Liefde; G Vauquelin
Journal:  Mol Cell Endocrinol       Date:  2008-06-21       Impact factor: 4.102

Review 10.  GRKs as Modulators of Neurotransmitter Receptors.

Authors:  Eugenia V Gurevich; Vsevolod V Gurevich
Journal:  Cells       Date:  2020-12-31       Impact factor: 6.600

View more
  3 in total

1.  G Protein-Coupled Receptors-Receptors With New Tricks Up Their Sleeves.

Authors:  Susan F Steinberg; George W Booz
Journal:  J Cardiovasc Pharmacol       Date:  2022-09-01       Impact factor: 3.271

2.  Regulator of G-Protein Signaling-4 Attenuates Cardiac Adverse Remodeling and Neuronal Norepinephrine Release-Promoting Free Fatty Acid Receptor FFAR3 Signaling.

Authors:  Alexandra M Carbone; Jordana I Borges; Malka S Suster; Anastasiya Sizova; Natalie Cora; Victoria L Desimine; Anastasios Lymperopoulos
Journal:  Int J Mol Sci       Date:  2022-05-22       Impact factor: 6.208

Review 3.  Short-Chain Fatty Acid Receptors and Cardiovascular Function.

Authors:  Anastasios Lymperopoulos; Malka S Suster; Jordana I Borges
Journal:  Int J Mol Sci       Date:  2022-03-18       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.